Information Provided By: 
Fly News Breaks for March 23, 2015
GILD
Mar 23, 2015 | 08:23 EDT
Baird said it would use any weakness in Gilead shares following the company's report of a patient having died while taking a heart drug at the same time as Gilead's hepatitis C drug as a buying opportunity. The firm sees a negligible commercial impact and reiterated its Outperform rating and $126 price target on Gilead shares.
News For GILD From the Last 2 Days
There are no results for your query GILD
